Clindamycin Drug Study
Clindamycin Drug Study
Clindamycin Drug Study
G. V.
Age
43 y.o
Height
52
Diagnosis
Sex
Female
Weight
66 kg
Author
M. M. Olmillo
Website
milkv.co.vu
A/N
youre welcome J
DRUG DATA
Generic name:
Clindamycin
CLASSIFICATION
Pharmacologic:
Lincosamide
antibiotic
Trade name/s:
Cleocin, Dalacin
MECHANISM OF
ACTION
Inhibits protein
synthesis in
susceptible bacteria,
causing cell death
Patients dose:
900mg q6o
Maximum dose:
2,700mg/day
Therapeutic:
Antibiotic
Onset:
Immediate
Minimum dose:
600mg/day
Availability:
Capsules 75,
150, 300mg;
granules for oral
solution 75
mg/5ml; injection
150mg/ml,
300mg/12mL,
600mg/14mL,
900mg/16mL,
300, 600,
900mg/50mL;
topical gel 1%;
topical lotion
1%; topical
suspension 1%;
vaginal cream
2%; vaginal
suppository
100mg
Pregnancy Category
Risk: B
Peak:
Minutes
Duration:
8-12 hr
Metabolism:
hepatic, 2-3 hr
Distribution:
Crosses placenta,
enters breast milk
Excretion:
Feces, urine
Topical:
Minimal systemic
absorption
INDICATIONS
General:
> systemic
administration:
serious infections
caused by
susceptible
strains of
anaerobes,
streptococci,
staphylococci,
penumococci
> parenteral:
treatment of
septicemia
> topical
dermatologic
solution:
treatment of acne
vulgaris
> vaginal
preparation:
treatment of
bacterial
vaginosis
CONTRAINDICATI
ON
ADVERSE
EFFECTS
Contraindicated with
allergy to clindamycin,
lactation
Systemic
CNS: cardiac arrest
(with rapid IV
transfusion)
Precaution:
Use cautiously in
newborns and infants
due to benzyl alcohol
content (associated with
gasping syndrome) and
in patients with tartrazine
sensitivity or hepatic or
renal impairment
GI:
pseudomembranou
s colitis
Interactions:
> drug-drug:increased
neuromuscular blockade
with neuromuscular
blocking agents;
decreased GI absorption
with kaolin, aluminium
salts
Hematologic:
neutropenia,
leukopenia
Hyppersensitivity:
rashes
Topical
dermatologic soln
CNS: fatigue,
headache
Dermatologic:
contact dermatitis,
dryness
Patients actual
indications:
Treatment of
serious infections
caused by
susceptible
strains of
anaerobes
GI:
pseudomembranou
s colitis, bloody
diarrhea
GU: urinary
frequency
Route:
IVTT
Source: 2011
Lippincotts NDG
Source: 2011
Lippincotts NDG
Source: 2011
Lippincotts NDG
Source: 2011
Lippincotts NDG
Source: 2011
Lippincotts NDG
Vaginal preparation
GU: cervicitis, vulvar
irritation
Source: 2011
Lippincotts NDG
NURSING
RESPONSIBILITIE
S
Before:
> check doctors order
> assess for allergy to clindamycin,
history of asthma or other allergies,
allergy to tartrazine
> assess history of renal impairment,
lactation, regional enteritis or
ulcerative colitis
> assess site of infection or acne,
skin color, lesions,
> take clients BP
During:
> verify patients identity
> administer the right drug with the
right dose at the right time
> state the importance and purpose
of the drug to the patient
> check the patency of the IV site
and IV line
> if hypersensitivity reaction occurs,
stop the administration immediately
After:
> regulate the IVF with the
prescribed flow rate
> monitor LFTs and renal function
tests, and blood counts
> report severe or watery diarrhea,
abdominal pain, inflamed mouth or
vagina, skin rash or lesions
> take full prescribed course of oral
drug. Do not stop taking without
notifying your health care provider
> document and record.